Recurrent Endometrial Serous Adenocarcinoma (DBCOND0091333)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT05231122	Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer	Bevacizumab Pembrolizumab	treatment	2	recruiting
NCT05870761	Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma	Dostarlimab Niraparib	treatment	2	recruiting
NCT00492778	Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer	Chloride ion Cisplatin Platinum	treatment	2	active_not_recruiting
NCT03325634	Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Primary Ovarian or Uterine Cancer	No drug interventions	treatment	1	completed
NCT03120624	VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer	Human interferon beta Ruxolitinib Sodium iodide Technetium Tc-99m pertechnetate	treatment	1	active_not_recruiting
NCT03914612	Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer	Carboplatin Paclitaxel Pembrolizumab	treatment	3	active_not_recruiting